Reuters logo
BRIEF-Veracyte says Anthem coverage for the Afirma gene expression classifier for use in thyroid cancer diagnosis
May 18, 2017 / 6:27 PM / in 7 months

BRIEF-Veracyte says Anthem coverage for the Afirma gene expression classifier for use in thyroid cancer diagnosis

May 18 (Reuters) - Veracyte Inc

* Veracyte announces Anthem coverage for the Afirma® gene expression classifier for use in thyroid cancer diagnosis

* Anthem Inc has issued positive coverage policy veracyte’s Afirma Gene Expression Classifier (GEC) for use in thyroid cancer diagnosis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below